In vivo CRISPR therapy successfully reduces hereditary angioedema attacks in first Phase III trial

Intellia Therapeutics has announced groundbreaking Phase III results for lonvoguran ziclumeran (NTLA-2002), its in vivo CRISPR gene editing therapy for hereditary angioedema (HAE), marking the first successful late-stage trial of an in vivo CRISPR treatment. The HAELO trial demonstrated an 87% relative reduction in monthly HAE attacks compared to placebo, with 62% of treated patients remaining attack-free without ongoing prophylactic medication. This achievement, detailed by researchers from Amsterdam UMC and published in The New England Journal of Medicine, signals a potential paradigm shift toward single-dose, curative genetic interventions for a debilitating chronic condition. Hereditary angioedema, characterized by unpredictable and life-threatening swelling attacks, has long burdened patients with the need for lifelong, often inconvenient, prophylactic therapies that still result in breakthrough attacks. Lonvoguran ziclumeran addresses this by delivering CRISPR/Cas9 components via a lipid nanoparticle directly to liver cells, where it inactivates the KLKB1 gene responsible for producing prekallikrein, thereby permanently lowering plasma kallikrein and the subsequent overproduction of bradykinin that drives HAE attacks. This innovative approach bypasses the challenges of chronic medication, offering the promise of durable, single-treatment efficacy. With these definitive Phase III results, Intellia Therapeutics has initiated a rolling Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA), aiming for a potential market launch in the first half of 2027. The success of the HAELO trial validates the immense potential of in vivo gene editing technology, setting a precedent that could accelerate the development of similar CRISPR-based therapies for a wide array of other genetic disorders. Regulators' review of lonvoguran ziclumeran will be closely watched by the biotech industry and patient communities, as it paves the way for a new era of precision medicine.